Literature DB >> 17452487

Combined therapies in a murine model of blastoschizomycosis.

Carolina Serena1, M Mar Rodríguez, Marçal Mariné, F Javier Pastor, Josep Guarro.   

Abstract

In a murine model of blastoschizomycosis, amphotericin B combined with micafungin, flucytosine or voriconazole did not improve the efficacy of fluconazole. However, such combinations can constitute therapeutic options for those cases where fluconazole fails.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17452487      PMCID： PMC1913274          DOI： 10.1128/AAC.00173-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  19 in total

Review 1.  Combination antifungal therapy.

Authors:  Melissa D Johnson; Conan MacDougall; Luis Ostrosky-Zeichner; John R Perfect; John H Rex
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

2.  [Pulmonary infection caused by Blastoschizomices capitatus].

Authors:  A Romano; S Giordano; P Di Carlo; L Abbagnato; F Sapuppo; G Lazzaro; R Tetamo; L Titone
Journal:  Infez Med       Date:  2005-09

3.  Activities of available and investigational antifungal agents against rhodotorula species.

Authors:  D J Diekema; B Petroelje; S A Messer; R J Hollis; M A Pfaller
Journal:  J Clin Microbiol       Date:  2005-01       Impact factor: 5.948

4.  Fluconazole and itraconazole resistance of yeasts isolated from the bloodstream and catheters of hospitalized pediatric patients.

Authors:  Gustavo Giusiano; Magdalena Mangiaterra; Viviana Garcia Saito; Florencia Rojas; Verónica Gómez; María Cristina Díaz
Journal:  Chemotherapy       Date:  2006-08-04       Impact factor: 2.544

Review 5.  Case report. Disseminated infection of Blastoschizomyces capitatus in a patient with acute myelocytic leukaemia.

Authors:  V Buchta; P Zák; A Kohout; M Otcenásek
Journal:  Mycoses       Date:  2001-12       Impact factor: 4.377

6.  Blastoschizomyces capitatus: an emerging cause of invasive fungal disease in leukemia patients.

Authors:  P Martino; M Venditti; A Micozzi; G Morace; L Polonelli; M P Mantovani; M C Petti; V L Burgio; C Santini; P Serra
Journal:  Rev Infect Dis       Date:  1990 Jul-Aug

7.  Increasing in vitro resistance to fluconazole in Cryptococcus neoformans Cambodian isolates: April 2000 to March 2002.

Authors:  Borann Sar; Didier Monchy; Mich Vann; Chantary Keo; Jean Louis Sarthou; Yves Buisson
Journal:  J Antimicrob Chemother       Date:  2004-07-14       Impact factor: 5.790

Review 8.  Invasive infections caused by Blastoschizomyces capitatus and Scedosporium spp.

Authors:  E Bouza; P Muñoz
Journal:  Clin Microbiol Infect       Date:  2004-03       Impact factor: 8.067

9.  Blastoschizomyces capitatus infection after contamination of fluids for intravenous application.

Authors:  M S Mathews; S Sen
Journal:  Mycoses       Date:  1998-11       Impact factor: 4.377

10.  Comparative in vivo activity of BAL4815, the active component of the prodrug BAL8557, in a neutropenic murine model of disseminated Aspergillus flavus.

Authors:  Peter A Warn; Andrew Sharp; Juan Mosquera; Jochen Spickermann; Anne Schmitt-Hoffmann; Markus Heep; David W Denning
Journal:  J Antimicrob Chemother       Date:  2006-10-27       Impact factor: 5.758
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.